Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
Open Access
- 26 May 2010
- journal article
- Published by Springer Science and Business Media LLC in Journal of Ovarian Research
- Vol. 3 (1), 13-10
- https://doi.org/10.1186/1757-2215-3-13
Abstract
Background Ovarian cancer is the most common cause of cancer related death from gynecologic tumors in the United States. The insidious nature of the disease precludes early diagnosis, therefore surgical debulking and chemotherapy are considered as standard treatment modalities for advanced stages. We investigated the effect of the LXR agonist, T0901317, on ovarian cancer cell proliferation and apoptosis as a potential therapeutic agent. Results T0901317 treatment resulted in a significant (P <0.001) inhibition of cell proliferation in a time- and dose-dependent manner in CaOV3, SKOV3 and A2780 cells. Western blot analysis demonstrated an induction of p21 and p27 with a concominant reduction in phospho-RB protein levels. Cell cycle analysis demonstrated a significant (P <0.001) arrest in the G1 cell cycle phase. Significant induction of Caspase-3 and BAX gene expression occurred with treatment. Induction of apoptosis was confirmed by significant (P < 0.001) elevation of caspase activity on FACS analysis, caspase-glo assay, BAX protein induction and decreased caspase 3 precursor protein expression on Western blot analysis. LXR α/β knockdown experiments did not reverse the anti-proliferative and cytotoxic effects of T0901317. Conclusions The LXR agonist, T0901317, significantly suppresses cell proliferation and induces programmed cell death in a dose- and time-dependent manner. Our results indicate that T0901317 induces its anti-proliferative and cytotoxic effects via an LXR-independent mechanism.Keywords
This publication has 26 references indexed in Scilit:
- Effects of diallyl disulfide (DADS) on expression of apoptosis associated proteins in androgen independent human prostate cancer cells (PC-3)Molecular and Cellular Biochemistry, 2008
- The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cellsBiochemical and Biophysical Research Communications, 2007
- Activation of Liver X Receptors and Retinoid X Receptors Induces Growth Arrest and Apoptosis in Insulin-Secreting CellsEndocrinology, 2007
- T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXRFEBS Letters, 2007
- The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase ExpressionCancer Research, 2006
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- The Nuclear Oxysterol Receptor LXRα Is Expressed in the Normal Human Breast and in Breast CancerMedical Oncology, 2004
- Nuclear Receptors and Lipid Physiology: Opening the X-FilesScience, 2001
- LXR, a nuclear receptor that defines a distinct retinoid response pathway.Genes & Development, 1995